EDIT: We have decided to reconsider our approach, due to issues with off-target binding of afamelanotide that would likely complicate intranasal delivery. Apologies to all who have contacted us about our technology. We will turn our focus towards developing novel MC1R agonist molecules, and can still be reached at info@chromavel.com - please reach out if you are interested in our progress.